Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $1.46 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,667 shares of the biopharmaceutical company’s stock after purchasing an additional 196 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $1,464,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Meyer Handelman Co. lifted its position in shares of Regeneron Pharmaceuticals by 11.4% in the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after purchasing an additional 435 shares during the period. Stifel Financial Corp raised its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after purchasing an additional 3,385 shares during the period. LPL Financial LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.3% during the 3rd quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after buying an additional 1,221 shares during the period. Finally, Monetary Management Group Inc. grew its stake in Regeneron Pharmaceuticals by 4.8% in the third quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock valued at $901,000 after acquiring an additional 50 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 8,095 shares of company stock worth $7,779,766 over the last three months. 8.83% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 1.0 %

NASDAQ:REGN traded down $9.32 during midday trading on Wednesday, hitting $960.65. The stock had a trading volume of 82,332 shares, compared to its average volume of 491,962. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a market capitalization of $105.44 billion, a price-to-earnings ratio of 28.65, a PEG ratio of 2.74 and a beta of 0.17. The stock has a 50-day moving average of $942.67 and a 200 day moving average of $899.44. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on REGN. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. UBS Group boosted their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $981.71.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.